- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Raynauds Phenomenon.
Displaying page 1 of 1.
EudraCT Number: 2014-000865-34 | Sponsor Protocol Number: AC-065C202 | Start Date*: 2014-09-16 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud's Phenomenon second... | |||||||||||||
Medical condition: Raynaud's Phenomenon secondary to Systemic Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002444-24 | Sponsor Protocol Number: HS-18-638 | Start Date*: 2020-02-18 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: An Exploratory Trial Assessing Vascular Digital Perfusion, Pharmacokinetics, Safety and Tolerability Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud’s ... | |||||||||||||
Medical condition: Raynaud’s phenomenon secondary to systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001899-38 | Sponsor Protocol Number: BAY63-2521/16787 | Start Date*: 2013-07-29 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Single dose, double-blind, placebo-controlled, single center, randomized cross-over study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after o... | |||||||||||||
Medical condition: Patients with 1° and 2° Raynaud’s phenomenon (RP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019009-40 | Sponsor Protocol Number: A7331010 | Start Date*: 2010-07-08 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: Estudio clínico de Fase 2A, multicéntrico aleatorizado, doble ciego, controlado con placebo y con un fármaco activo, de diseño cruzado con dos cohortes y dos dosis, para la evaluación de la eficaci... | |||||||||||||
Medical condition: Tratamiento del vasospasmo en el fenómeno de Raynaud primario y secundario. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) CZ (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013468-37 | Sponsor Protocol Number: Protocol code BA7 | Start Date*: 2010-09-29 | ||||||||||||||||
Sponsor Name:Royal National Hospital for Rheumatic Disease | ||||||||||||||||||
Full Title: A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon. | ||||||||||||||||||
Medical condition: Primary Raynaud's Phenomenon and Systemic Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003203-35 | Sponsor Protocol Number: VP-C21-004 | Start Date*: 2019-12-13 | ||||||||||||||||
Sponsor Name:Vicore Pharma AB | ||||||||||||||||||
Full Title: A Phase 2, single-center, randomised, double-blind, placebo-controlled, cross-over, cold challenge study investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud’s ... | ||||||||||||||||||
Medical condition: Systemic sclerosis (SSc) Raynaud’s phenomenon (RP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-024005-13 | Sponsor Protocol Number: 3098009 | Start Date*: 2011-03-11 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to syste... | |||||||||||||
Medical condition: Raynaud's phenomenon secondary to systemic sclerosis (Raynaud's syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002081-13 | Sponsor Protocol Number: GS-2001 | Start Date*: 2020-09-08 | ||||||||||||||||
Sponsor Name:Gesynta Pharma AB | ||||||||||||||||||
Full Title: A Phase II, randomised, multi-centre placebo-controlled, double-blind study to investigate the safety of GS-248, and efficacy on Raynaud’s phenomenon (RP) and peripheral vascular blood flow in pati... | ||||||||||||||||||
Medical condition: Raynaud's phenomenon (RP) in patients with Systemic sclerosis (SSc) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004613-24 | Sponsor Protocol Number: 01 | Start Date*: 2016-05-30 |
Sponsor Name:Radboudumc | ||
Full Title: Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial. | ||
Medical condition: (very early) systemic sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001353-16 | Sponsor Protocol Number: BAY63-2521/16277 | Start Date*: 2015-04-17 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) | |||||||||||||
Medical condition: diffuse cutaneous systemic sclerosis (dcSSc) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.